CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low

Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript

On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts

Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K Estimate

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst consensus estimate of $(3.00) by 51.33 percent. This is a 78.84 percent increase over losses of $(6.90) per share from the

Co-Diagnostics Announces FDA Submission Of Dual 510(k) With Concurrent CLIA Waiver Application For Co-Dx PCR Flu A/B & RSV Point-Of-Care Test

JP Morgan Reinstates Underweight on Emergent BioSolutions

JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.

HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.

U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated

https://www.cdc.gov/measles/data-research/index.html